Introduction
Standard treatment in differentiated thyroid carcinoma requires total or near-total thyroidectomy and high-dose radioiodine ( 131 I) therapy to completely ablate the thyroid remnants [1, 2] .
Over time, the extensive therapeutic effects of oral b-emitting 131 I for the treatment of well-differentiated thyroid carcinoma have been well established [1, 2] . Apart from specific uptake by thyroid tissue, 131 I actively also accumulates in the acinar cells of salivary glands through an adenosine triphosphate-dependent Na + /K + /2Cl -cotransport mechanism [3] . The concentration of iodide in the saliva is about 30-40 times higher than that in the plasma. Accordingly, when the salivary glands are exposed to high concentrations of 131 I after therapy, the radiation dose is sufficient to cause an injury and rapidly affect the salivary gland function [4] [5] [6] . As a result, salivary gland dysfunction is the most common side effect and is associated with dry mouth, swelling difficulties, dental diseases, and loss of taste, impairing the quality of life of thyroid cancer patients for the duration of their life after 131 I therapy [7] [8] [9] [10] .
Salivation-inducing snacks, such as lemon candy, have been presumed to be helpful in the prevention of side effects in salivary glands accruing from 131 I therapy. However, despite its frequent use, there is no established evidence indicating that lemon candy, with any specific dosage or timing of administration, actually decreases the extent of injury to the salivary glands after 131 I therapy [4] . In contrast, even under salivary gland stimulation, parenchymal damage and functional impairment could be seen after high-dose 131 I therapy using quantitative or semiquantitative salivary gland scintigraphy (SGS) [4, 11, 12] .
The damaging effects of ionizing radiation are mediated by the formation of free radicals, which are highly reactive in removing hydrogen atoms from fatty acids, causing lipid peroxidation and consequently cell death [5] . Vitamin E is a natural component of cell membranes and is the strongest antioxidant of the tocopherols, reacting quickly with peroxyl radicals and forming a tocopheroxyl radical, which interrupts the free radical chain reaction [5] . Some radioprotective effects of vitamin E have already been recognized in experimental animals [5, 13, 14] . The administration of vitamin E before external g irradiation may protect salivary gland function in rats [5] . In addition, presupplementation with vitamin E seems to offer a significant radioprotection for salivary glands against 131 I-induced radiation injury in mice [14] . However, the radioprotective effect of vitamin E on human salivary glands exposed to therapeutic doses of 131 I has not been evaluated so far.
The aim of this study was to evaluate whether supplementation with vitamin E could diminish the radiation-induced damage to major salivary glands, using a semiquantitative scintigraphic method for measuring the secretory and excretory salivary function.
Methods

Patients
This double-blind randomized clinical trial study was approved by the ethics committee of Tehran University of Medical Sciences. From June 2006 to February 2007, 36 postsurgical differentiated thyroid cancer patients aged less than 55 years, who were referred to our institute for 131 I therapy to ablate the remnant thyroid tissue or to treat metastatic tumor, were enrolled in this study. All patients were in a hypothyroid state with serum thyroid stimulating hormone levels higher than 25 mIU/l. Patients with xerostomia, previous salivary gland dysfunction, salivary stone or tumor, those who had undergone head and neck radiotherapy previously, who had known rheumatological diseases such as Sjögren's disease, who had been administered 131 I earlier, who had known liver disease, had taken drugs influencing salivary gland function, such as antihistaminic agents, b-blockers, atropine, benzodiazepines, tricyclic antidepressants, and antipsychotic drugs in the past 2 weeks, and pregnant women were excluded from the study.
After signing the written informed consent form, all patients were allocated to one of two groups using a permuted block randomization method: the vitamin E group, comprising 19 patients, and the control group, comprising 17 patients. The 19 patients in the vitamin E group received vitamin E orally at a dose of 800 IU/day for 5 weeks, from 1 week before to 4 weeks after 131 I therapy. The 17 patients in the control group received a placebo in the same order and for the same duration.
Salivary gland scintigraphy
On the day of admission, SGS was performed for all patients. The patients were positioned supine with hyperextended neck and the images were obtained on a large field of view using a single-head gamma camera equipped with a low-energy, all-purpose collimator. Each patient received an intravenous injection of 370 MBq of 99m Tc-pertechnetate. Immediately after administration, sequential dynamic images were taken at 1 min/ frame on a 128 Â 128 matrix with a zoom factor of 1.55 for 30 min. The energy window was 20% around the 140 keV photopeak of 99m Tc. Twenty minutes after the injection, 5 ml of lemon juice (50% concentrated) was administered through a syringe into the patient's mouth to stimulate salivary secretion.
Salivary gland function was evaluated semiquantitatively by two expert nuclear medicine physicians. Circular regions of interest (ROIs) were drawn manually around both the parotid and submandibular glands. To detect the background activity, ROIs of equal sizes were also drawn in the temporal region.
From these ROIs the following parameters were calculated: (a) the first-minute uptake ratio (FUR), which is C 1 /C 2 , where C 1 is the mean counts in ROIs of the salivary glands and C 2 is the mean counts in ROIs of the background during the first minute of injection; (b) the maximum uptake ratio (MUR), which is C 3 /C 4 , where C 3 is the highest mean count in ROIs of the salivary glands after injection and C 4 is the mean counts in ROIs of the background synchronized with the highest mean count in ROIs of the glands; (c) the maximum secretion percentage (MSP), which is (MUR -C 5 /C 6 ) Â 100/MUR, where C 5 is the lowest mean count in ROIs of the salivary glands after stimulation with lemon juice and C 6 is the mean counts in ROIs of background synchronized with the lowest mean count in ROIs of the glands; and (d) the excretion fraction (EF), which is (C 3 -C 4 -C 5 + C 6 ) Â 100)/C 3 -C 4 ).
Follow-up assessments
All patients underwent a second SGS 6 months after 131 I therapy in an off-levothyroxine hypothyroid state with thyroid stimulating hormone levels higher than 25 mIU/l, similar to the values obtained in the baseline scan. All of the above-mentioned parameters were also calculated for the recent scintigraphies in the same way, and consequently the markers of functional changes were calcu- the two groups. The categorical variables were compared between the groups using Fisher's exact test. Statistical comparisons between the two phases within the same group were made using the Wilcoxon signed-rank test. Statistical significance was set at P-values less than 0.10.
Results
The baseline demographic and scintigraphic data of patients are shown in Table 1 . There was no statistically significant difference between the two groups with respect to age, sex, histology of tumor, type of surgery, 131 I dose, and baseline scintigraphic parameters, that is FUR, MUR, MSP, and EF, pointing to the fact that the two groups were comparable with respect to their baseline characteristics (Table 1 ).
There was no statistically significant difference in scintigraphic findings between the two phases (i.e. before and after treatment) in the vitamin E group ( Table 2) . As a result, no evidence of function deterioration was noted in this group.
The scintigraphic data of the control group before and after 131 I treatment are summarized in Table 3 . As noted, MSP and EF of the right submandibular gland and EF of the left parotid gland are significantly decreased following 131 I treatment in this group, compared with baseline values (Table 3) . Table 4 shows a comparison between the vitamin E and control groups regarding scintigraphic markers of functional changes after treatment. As shown in this table, DFUR for the right parotid and DEF for the left parotid glands differ significantly between the two groups in support of less functional deterioration in the patients receiving vitamin E. Figures 1 and 2 show the pretherapy and post-therapy salivary gland scintigraphies of a patient pretreated with vitamin E. The corresponding scintigraphies of a control patient have also been shown in Figs 3 and 4.
Three out of 38 parotid glands (7.9%) in the vitamin E group versus nine out of 34 parotid glands (26.5%) in the control group revealed more than 15% decline in EF (P = 0.035).
Discussion
As differentiated thyroid cancer has a good prognosis, the long-term side effects of high-dose 131 I therapy have important implications for the patient's quality of life. Radiationinduced xerostomia or hyposalivation in 131 I-treated patients results in oral discomfort and compromised oral health, causing great difficulty that is life-long and impairing the patient's quality of life. Unfortunately, many treatment modalities, such as use of salivary stimulants and saliva substitutes, are palliative and generally offer only shortterm relief from symptoms [15, 16] . The prevention of salivary damage is therefore an important task in these patients.
A single activity of 6 GBq is thought to result in absorbed radiation doses of about 1 Gy to the parotid and 3 Gy to the submandibular salivary glands, inducing more than 30% loss of parenchymal function as measured by salivary scintigraphy [17] . Correspondingly, a cumulative administered dose of about 24 GBq may result in 4 Gy for the parotid gland and 12 Gy for the submandibular gland, leading to a 90% loss of function in these glands [17] . Meanwhile, serous cells, which are found almost exclusively in the acini of the parotid glands, are assumed to be more radiosensitive than mucous cells, which predominantly exist in submandibular glands, because serous secretory granules are rich in transition metals such as Zn 2 + , Fe 2 + , and Mn 2 + , which may leak into the cytoplasm, causing autolysis and inducing cell death. Further, it is clinically accepted that the most sensitive glands affected by 131 I are the parotid glands, whereas the submandibular and sublingual glands are somewhat more resistant to radiation [12, 18] .
SGS with
99m Tc-pertechnetate is an easy, safe, and noninvasive method for evaluating the major functions of salivary glands [3] . Although the reduction in salivary gland function based on the findings specified on scintigraphy does not necessarily reflect the incidence of the corresponding clinical complications, such as dry mouth, the rate of incidence of these complications may subsequently increase in patients with scintigraphically impaired salivary function [4, 19] . In semiquantitative SGS studies, the calculation of three functions (perfusion, uptake, and secretion) has been often carried out and its values widely used. The correlation between 99m Tc uptake into the salivary glands and saliva secretion has also been established [20] . Helman et al. [20] , using semiquantitative methods, revealed that 99m Tc substitutes for Cl -in the Na + /K + /Cl -salivary cotransport system and therefore may serve as a measure of saliva secretion.
It is well documented that there is a positive correlation between the cumulative activity of 131 I and the rate of scintigraphically impaired function of the salivary glands. In the study by Albrecht et al. [21] , the researchers showed that after a dose of 0.3 Ci there was a change in T max values and maximal excretion capacity in 30% of patients, whereas after a dose of 0.5-1 Ci the corresponding changes were detected in 60 and 80% of patients; consistently, after very high doses of 1.1-3.2 Ci, twothirds of patients showed evidence of abnormal T max , and reduced or absent salivary excretion capacity was seen in all patients.
The damaging effects of ionizing radiation are induced by free radicals through a cytotoxic process caused by lipid peroxidation that finally leads to cell death [5] . A potentially successful strategy to prevent salivary gland damage after 131 I therapy is the prophylactic use of amifostine [11] . However, amifostine as a prophylactic drug is currently underutilized because of limited availability, high cost, severe side effects, and lack of sufficient evidence favoring its radioprotective impact on humans [11, 22] .
Another possible method of reducing salivary gland radiation during radioactive iodine treatment is by increasing salivation using sour candy, lemon juice, or vitamin C tablets. However, the sour prescription has been shown to have little effect on the absorbed dose of the salivary glands [23] . Similarly, current evidence suggests that, despite the use of salivation-inducing snacks, functional impairment of salivary glands may occur after high-dose 131 I therapy in thyroid cancer patients [4, 12, 24] . Some researchers even reported that the use of lemon candy in close temporal proximity to 131 I administration leads to increased salivation and therefore to increased salivary gland blood flow, which in turn results in more 131 I uptake and subsequently more radiation and more damage to the salivary gland function [4] . However, no well-controlled clinical trial has been conducted so far to test this assumption.
Although it is generally accepted that the use of antioxidants may provide some degree of protection against ionizing radiation especially on the basis of animal experiments, known antioxidant radioprotectors have not been extensively prescribed to patients exposed to different levels of radiation [13] . Some nutrients such as vitamin E not only have the advantage of low toxicity but also exert a natural radioprotective effect when administered at pharmacological doses. The protective effects of vitamin E against radiation-induced chromoso- mal aberrations and micronuclei have been established in rodents [13] . Previous studies on rats have shown that vitamin E and other antioxidant vitamins, by decreasing oxidative stress, exert some degree of protective effect against radiation-induced injuries such as oral mucositis, myelosuppression [25] , intestinal injuries [26] , lipid and DNA damage to the liver [27] , and cataract [28] . Protection against radiation-induced damage in small bowel crypts of rats [29] , modification of micronucleus induction by g rays in mice [30] , and in-vitro reduction in the number of micronuclei in human lymphocytes before and after g-ray irradiation have also been reported by others [31] . More relevantly, in a study conducted on the radioprotective effect of vitamin E on the salivary gland function of irradiated rats, it was demonstrated that significant protection of salivary flow and volume could be achieved 30 days after irradiation in the group pretreated with vitamin E in relation to the control group [5] . In all of the above-mentioned studies the rodents were externally irradiated. The available data on the use of antioxidants for radioprotection of salivary glands against internal exposure to b-emitting radioactive iodine are limited. In a recent study, it was shown that presupplementation with vitamin E against a single dose of 3.7 MBq 131 I in mice may be associated with a marked beneficial antioxidant effect on salivary glands [32] .
In contrast to the numerous studies performed on animals, only a few reports are available on the effect of vitamin E supplementation against radiation-induced injuries to the salivary gland of humans after external or internal irradiation. In a study on patients who had undergone external radiation therapy against oral cancer, a considerable preservation of salivary flow rate and significant maintenance of some other salivary parameters such as pH, protein, amylase, sodium, and potassium contents were observed in the group with vitamin E supplementation as compared with the control group [33] .
On the basis of the above-mentioned studies, vitamin E seems to have an important radioprotective effect on salivary gland function; however, no investigation has been performed so far with regard to the corresponding effects against 131 I therapy in humans [5] .
To the best of our knowledge, our study is the first to investigate the radioprotective effect of vitamin E against radiation-induced damage to the salivary glands after a single-dose of 131 I therapy in thyroid cancer patients. In our study there was no significant decrease in salivary gland function after 131 I therapy in patients pretreated with vitamin E, whereas a significant decline was noted in the MSP and EF of the right submandibular and EF of the left parotid gland in the control group (Tables 2 and 3) . Notably, there was no difference between the two groups at the beginning of the study, which in turn suggests that both groups were selected from a population with the same characteristics. In addition, the DEF of the left parotid glands in the control group differed significantly from that of the vitamin E group (Table 4 ). Significant deterioration of parotid gland excretion (more than 15% decrease in EF) was less frequent in patients pretreated with vitamin E when compared with the control group (7.9 vs. 26.5%).
Conclusion
Our study demonstrated a significant benefit from vitamin E consumption for the protection of salivary glands against radiation-induced dysfunctions during single-dose 131 I therapy among patients with differentiated thyroid cancer. However, we recommend further studies with larger sample sizes and different cumulative doses of 131 I to reach a more comprehensive conclusion with respect to these patients.
